Eli Lilly Shares Surge on Raised Sales Forecast
Eli Lilly & Co. raised its full-year sales forecast as demand for its blockbuster obesity and diabetes drugs continues to surge. Speaking on "Bloomberg Open Interest," Bloomberg's Madison Muller also discusses the implications for Novo Nordisk. (Source: Bloomberg)